Dana-farber Cancer Institute

This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor, can be safely combined with other immune-boosting drugs to treat melanoma. The goal is to see if this combination helps the body's immune system better recognize and attack c…

This study is testing the safety and best dose of a new three-drug combination for children and young adults whose acute lymphoblastic leukemia (ALL) has returned or not responded to standard treatments. The drugs—ribociclib, everolimus, and dexamethasone—work together to try to …

This study is testing a new, longer-lasting version of a standard chemotherapy drug (asparaginase) for children and teens with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. Researchers want to see if giving this new drug, called SC-PEG, every 3 weeks into a vein w…

This early-stage study is testing a personalized vaccine designed to help the immune system recognize and attack follicular lymphoma cells. The vaccine is custom-made for each participant using genetic information from their own tumor. Researchers will give the vaccine, sometimes…

This study is testing whether the drug acalabrutinib can help control recurrent or treatment-resistant lymphoma that has spread to the brain or spinal cord. The trial will enroll about 49 adults who have already tried at least one other treatment for this aggressive cancer. Resea…

This study is testing whether using two targeted drugs together is safe and effective for controlling advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. It is for adults who have not yet received any treatment for their advance…

This study is testing whether a CAR-T cell therapy called cilta-cel can safely and effectively treat people with high-risk smoldering myeloma—an early, pre-cancerous stage of multiple myeloma. Researchers will collect and modify participants' own immune cells to target and destro…

This study is testing the safety and effectiveness of combining two drugs, venetoclax and inotuzumab ozogamicin, for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or hasn't responded to previous chemotherapy. The main goal is to find the highest safe …

This study is testing a new approach to personalizing breast cancer treatment. It aims to see if doctors and patients are willing to adjust the amount of chemotherapy given after surgery, based on how well the cancer responded to treatment before surgery. The study involves 100 a…

This study is testing a drug called T-DM1 to see if it can help prevent a specific type of breast cancer (HER2-positive) from returning after surgery in patients aged 60 and older. The drug is designed to target cancer cells directly, which may lead to fewer side effects compared…

This study is testing whether adding the drug ipilimumab to the approved drug nivolumab can help control Hodgkin lymphoma that has come back or stopped responding to other treatments. It will involve about 13 adults whose cancer got worse after a prior type of immunotherapy. Part…

This study is testing whether combining a targeted radiation procedure (stereotactic radiosurgery) with an immunotherapy drug (atezolizumab) works better than either treatment alone for triple-negative breast cancer that has spread to the brain. The goal is to see if the radiatio…

This study is testing whether some women with early-stage, low-risk breast cancer can safely skip radiation treatment after having a lumpectomy (breast-conserving surgery). Researchers are using a special tumor test called Prosigna to identify patients who have a very low risk of…

This study tested a daily low-dose injection of a drug called IL-2 for people with chronic graft-versus-host disease (cGVHD) who did not respond well to standard steroid treatment. The goal was to see if adding IL-2 could help control the condition and allow doctors to reduce ste…

This study is testing whether adding the drug eribulin to standard chemotherapy works better when given before surgery for a specific aggressive type of breast cancer (HER2-negative inflammatory breast cancer). Researchers want to see if this drug sequence helps eliminate more ca…

This early-stage study is testing whether giving the immunotherapy drug pembrolizumab before surgery can boost the immune system's attack on recurrent glioblastoma, a fast-growing brain cancer. The research involves 60 adults whose cancer has returned after initial treatment. Doc…

This study is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—is a safe and effective first treatment for chronic lymphocytic leukemia (CLL). The trial involves 72 adults with CLL who have not had prior treatment but need it based on their…

This study tested whether regular phone calls from an exercise coach could help people who recently finished treatment for early-stage breast or colorectal cancer become more physically active. Research suggests staying active after cancer may lower the chance of the cancer comin…

This study is testing a drug called pembrolizumab for people with rare, aggressive cancers of the immune system (like certain lymphomas and histiocyte/dendritic cell sarcomas) that have come back or stopped responding to standard treatments. The drug aims to help the body's own i…

This study is testing whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help control advanced, rare cancers of the urinary and reproductive systems. It is for adults whose cancer has spread and who have few other treatment options. The main goal is t…

This study is testing whether a 16-week exercise program can reduce harmful inflammation in body fat for overweight breast cancer survivors who have finished treatment. Researchers want to see if lowering this inflammation might help decrease the risk of the cancer returning. The…

This study is testing a new combination of two oral drugs, duvelisib and venetoclax, for adults with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or stopped responding to prior treatment. The first part of the study aims to find a safe dose when the…

This study is testing if adding an immunotherapy drug called nivolumab to standard chemotherapy (carboplatin) works better for controlling advanced triple-negative breast cancer that has spread. It involved 78 patients whose cancer had not been treated for its spread. The main go…

This study is testing whether the drug regorafenib can help control metastatic medullary thyroid cancer that has continued to grow despite prior treatments. It is for adults whose cancer has worsened within the last 6 months and who have already tried at least one other targeted …

This study is testing three different drug combinations for advanced breast cancer that has continued to grow despite prior hormone therapy and a specific type of targeted drug (a CDK4/6 inhibitor). It aims to see if continuing the targeted drug, possibly with an added immunother…

This early-stage trial is testing whether a combination of two immune-based treatments is safe for patients whose blood cancer has returned after a stem cell transplant. The study involves 25 adults with conditions like acute myeloid leukemia or myelodysplastic syndromes. Researc…

This study is testing an experimental drug called AZD1775 to see if it is safe and effective for women with a specific, hard-to-treat form of uterine cancer that has come back or persisted after prior treatment. The drug works by blocking a protein that helps cancer cells grow an…

This early-stage study is testing a new drug called KPT-330 in children and young adults whose leukemia has returned or stopped responding to standard treatments. The main goal is to find the highest dose that can be given safely without causing severe side effects. Researchers w…

This early-stage study is testing whether two already-approved leukemia drugs—ibrutinib and obinutuzumab—are safe when given together and in what order. It involves 54 adults whose chronic lymphocytic leukemia has returned or stopped responding to previous treatments. The main go…

This early-stage study is testing whether adding the drug venetoclax to standard chemotherapy is safe for adults newly diagnosed with acute myeloid leukemia (AML). The main goal is to find the highest dose of venetoclax that can be given safely alongside chemotherapy. Researchers…

This study is testing whether combining two drugs, olaparib and ceralasertib, can help control osteosarcoma (a type of bone cancer) that has come back or stopped responding to standard treatments. It is for patients aged 12 to 40. The main goal is to see if this combination can s…

This early-stage study is testing the safety of combining two experimental drugs, palbociclib and gedatolisib, for people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the highest dose of this drug combination that patients ca…

This study is testing a new drug called IPI-145 in combination with a standard chemotherapy regimen (FCR) for younger adults who have never been treated for chronic lymphocytic leukemia (CLL). The first part aims to find the safest dose, and the second part aims to see how well t…

This study compares two different drug combinations given before surgery to shrink tumors in people with stage II-III HER2-positive breast cancer. About 174 participants were randomly assigned to receive either a newer drug combination (margetuximab) or the standard combination (…

This study is testing whether the chemotherapy drug lenalidomide can help control three rare disorders where the body makes too many immune cells. Researchers are enrolling 12 adults with Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma who need syst…

This study is testing whether a chemotherapy drug called clofarabine can help control Langerhans cell histiocytosis (LCH) and related disorders when they have come back or not responded to previous treatments. It is enrolling 25 participants of all ages who have active disease an…

This early-stage study is testing whether adding an experimental drug called ACY-1215 to existing leukemia medications (ibrutinib or idelalisib) is safe and tolerable for adults with chronic lymphocytic leukemia (CLL) that has returned after prior treatment. The main goal is to f…

This study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone—for people newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goals were to find the safest dose of the drug combination and to see how well it worked to control the …

This early-stage safety study is testing a new combination treatment for chronic graft-versus-host disease (cGVHD) that doesn't improve with standard steroid therapy. The treatment involves giving patients special anti-inflammatory immune cells (Tregs) collected from their origin…

This early-stage study is testing the safety and effectiveness of combining two drugs, olaparib and sapacitabine, for people with advanced breast cancer linked to a BRCA gene mutation. The main goals are to find the safest dose and see if the combination can shrink tumors. It is …

This study is testing a faster, daily schedule for increasing the dose of the drug venetoclax in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this accelerated 5-day schedule is as safe as the standard 5-week schedule,…

This study is testing if starting with a lower dose of the cancer drug abemaciclib and slowly increasing it is easier for patients to tolerate than the standard full dose. It involves 90 people with early-stage, high-risk, hormone-positive breast cancer who have already had surge…

This study is testing whether two drugs, abemaciclib and atezolizumab, can help control advanced prostate cancer that has spread and no longer responds to standard hormone treatments. The trial is enrolling men to receive one drug, the other, or both together, to see which approa…

This study tested a new system in a lung cancer clinic to help patients quit smoking. Researchers wanted to see if staff asked patients about smoking and offered them proven help like medication or counseling. They measured success by checking if patients actually quit, using bre…

This early-stage study is testing if the drug Talazoparib can help control two types of blood cancer (AML and MDS) in patients whose cancers have a specific genetic change called a cohesin mutation. The drug works by blocking a protein that helps cancer cells repair themselves, w…

This study is testing whether the drug niraparib can help control advanced pancreatic cancer in patients whose tumors have specific genetic mutations affecting DNA repair. The trial is enrolling 32 adults whose cancer has progressed after at least one prior treatment and who have…

This study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control rare, aggressive cancers in children and young adults. The trial is for patients whose cancers have returned or haven't responded to standard treatments. Researchers…

This study is testing if using two drugs, osimertinib and gefitinib, together works better than one alone for people newly diagnosed with a specific type of advanced lung cancer (EGFR mutation). The main goal is to see if this combination can control the cancer for longer by tryi…

This study aims to find better treatments for children and young adults whose leukemia has returned, hasn't responded to standard therapy, or is considered high-risk. Researchers analyze the genetic makeup of a patient's cancer cells to see if they can recommend a specific, targe…

This study is testing an experimental drug called abemaciclib for adults with glioblastoma, an aggressive brain cancer that has returned after initial treatment. The main goals are to see if the drug reaches the brain tumor effectively and if it can help slow the cancer's progres…

This study is testing whether adding the drug ruxolitinib to standard chemotherapy before surgery helps control triple-negative inflammatory breast cancer, a particularly aggressive form. Researchers are enrolling 23 adults with this specific cancer type to see if blocking a part…

This study is testing whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help control advanced breast cancer that has spread and has a high number of genetic mutations. The trial is enrolling 30 people with a specific type of breast cancer (HER2-negat…

This study is testing whether two immunotherapy drugs, nivolumab alone or combined with ipilimumab, can help control recurrent meningioma brain tumors. It involves 40 adults whose tumors have returned or progressed after prior treatments like surgery or radiation. The main goal i…

This study is testing whether adding a newer targeted drug called ibrutinib to a standard chemotherapy combination (FCR) is safe and more effective for younger patients with CLL who have not yet received any treatment. The main goal is to see if this combination can lead to a dee…

This study is testing whether a targeted radiation drug called 177Lu-PSMA-617 can help control advanced kidney cancer that has spread. The treatment works by seeking out cancer cells and delivering radiation directly to them. The trial involves about 24 patients whose cancer has …

This study is testing whether combining two existing cancer drugs, copanlisib and venetoclax, can help control an aggressive type of lymphoma called DLBCL that has returned or stopped responding to other treatments. The first part of the study aims to find a safe dose, and the se…

This early-stage study is testing the safety of a new, personalized vaccine designed to teach the immune system to attack a patient's specific melanoma. The vaccine is given alongside two approved immunotherapy drugs. The main goal is to find a safe dose for a new way of giving o…

This study is testing whether a 16-week home exercise program can slow the progression of prostate cancer in Black men who are on active surveillance (monitoring without immediate treatment). Researchers want to see if high-intensity interval training (HIIT) can help control canc…

This is a first-in-human safety study testing a genetically engineered virus, rQNestin34.5v.2, as a potential treatment for recurrent malignant brain tumors (gliomas). The virus is designed to infect and kill only cancer cells while sparing healthy brain tissue. The main goals ar…

This study is testing whether patients with advanced HER2-positive breast cancer can safely stop their targeted treatment after having their cancer under control for at least three years. The trial involves 82 participants who will either continue treatment or stop it, with resea…

This study is testing a precise form of radiation therapy (SBRT) to control cancer that has spread to the spine or other bones. It aims to see if this approach better stops tumor growth in the treated area and relieves symptoms like pain, while potentially causing fewer side effe…

This study is testing whether giving immunotherapy drugs before standard surgery can help shrink oral cavity cancer tumors. It involves about 30 adults with a specific type of head and neck cancer who are scheduled for surgery. Researchers want to see if the drugs, nivolumab alon…

This study is testing whether surgery to remove a small, early-stage breast cancer (called DCIS) is enough treatment on its own, without needing follow-up radiation therapy. It involves 158 women with low- or intermediate-grade DCIS. The goal is to see if this simpler approach ke…

This study is testing a more personalized approach to treating children and young adults with acute lymphoblastic leukemia (ALL), the most common childhood cancer. Researchers are using updated risk factors to determine treatment intensity and testing a new way to dose a key chem…

This study is testing a safe dose of a special dye and a near-infrared light to help surgeons see and remove the first lymph node that drains from a lung tumor. By finding and analyzing this 'sentinel' node more precisely, doctors hope to better detect if cancer has spread. The s…

This study is testing a genomic test called Prosigna to see if it helps doctors and patients choose the best personalized treatment before breast cancer surgery. Researchers will give the test to 60 women with hormone-positive, HER2-negative breast cancer to see if the results ch…

This study is testing whether yearly full-body MRI scans can help find cancer early in people with inherited conditions that greatly increase their cancer risk, like Li-Fraumeni syndrome. It involves 150 adults and children who have these genetic risks, and they will get scanned …

This study is testing whether the drug daratumumab can prevent or delay the progression to active multiple myeloma in people with high-risk early-stage conditions (MGUS or smoldering myeloma). The trial involves 42 participants who have these conditions but do not yet have sympto…

This study is testing whether a phone counseling program can help heavy smokers quit and learn about lung cancer screening. About 250 participants aged 55-77 who smoke heavily will receive either an intensive 8-session phone program or standard care. Researchers will compare quit…

This study is testing whether metformin, a common diabetes medication, can prevent people with early blood cell conditions (MGUS and smoldering myeloma) from developing full multiple myeloma, a type of blood cancer. About 60 participants will take either metformin or a placebo pi…

This study is testing whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer stay more active and protect their heart health while they undergo chemotherapy. About 135 participants are randomly assigned to try eith…

This study is testing if a form of acupuncture using mild electrical stimulation can help reduce pain from nerve damage caused by chemotherapy. It involves 255 cancer survivors who have finished treatment but still suffer from this painful side effect. Participants are randomly a…

This study tests two online education programs to help young women manage sexual health changes after cancer treatment. Researchers are comparing group video sessions with individual self-management sessions to see which approach works better. The goal is to help participants imp…

This study is testing a web-based portal designed to help young women (ages 18-39) who have been diagnosed with breast cancer. The portal helps monitor common symptoms like vaginal dryness and fatigue, provides self-management information and resources, and offers a way to connec…

This study is testing whether yoga can help reduce nerve pain caused by chemotherapy, a common side effect for cancer survivors. Researchers are comparing yoga classes to educational sessions and standard medical care to see which best improves pain, balance, and quality of life.…

This study is testing whether a 6-session coaching program called PRISM is practical and helpful for young adults (ages 18-39) with cancer who are experiencing moderate anxiety or depression. The program teaches skills like stress management and goal setting. Researchers are enro…

This study aims to find the best way to educate family members of pancreatic cancer patients about genetic testing. Researchers will compare two online education methods to see which one encourages more people to get tested for inherited cancer risk genes. About 1,000 adult relat…

This study aims to understand the experiences of older adults (age 70+) with breast cancer to find ways to improve their care and health outcomes. Researchers are following a group of 253 patients to learn about the barriers they face, their treatment patterns, and how their phys…

This study collects blood and bone marrow samples from people with multiple myeloma and related blood cancers to build a research database. Participants also provide medical history through a questionnaire. The goal is to help scientists understand these diseases better and devel…

This study aims to understand how women feel physically and emotionally after treatment for certain pre-cancerous breast conditions. Researchers surveyed over 900 women who had been diagnosed with these conditions to learn about their pain levels and overall experience. The goal …

This study is testing whether summaries created by an artificial intelligence (AI) program can help doctors and patients with advanced cancer have better conversations about serious care goals. The AI reviews past medical records to create a summary of what's important to the pat…

This study looked at whether exercise and mind-body programs in the weeks between breast cancer diagnosis and surgery could help women feel less stressed and improve their mood. Researchers also checked if these activities caused any changes in breast cancer cells or blood hormon…

This study is testing a new online tool called AYA-RISE, which includes a chatbot and information portal, to see if it helps teenagers and young adults with inherited cancer risk syndromes. The goal is to improve how these young people and their families talk about their risk and…

This study aims to better understand the experiences of young women diagnosed with breast cancer. It follows over 1,300 women aged 40 and under for at least 10 years after their diagnosis. Researchers collect surveys, blood samples, and tumor tissue to learn about the disease, tr…

This study is testing a heart screening program for people who survived Hodgkin's disease after receiving chest radiation at least five years ago. Participants undergo heart tests and fill out quality-of-life questionnaires. The goal is to see if regular heart check-ups are pract…

This study aims to understand if an inherited change in a gene called EGFR increases a person's risk of developing lung cancer, particularly in people who have never smoked. Researchers are recruiting people with a specific cancer mutation (T790M) and their family members to prov…

This study is exploring how starting an exercise program might change markers in breast tissue and blood in women with dense breasts. Researchers want to understand the biological reasons why exercise might lower breast cancer risk. The study involves 60 inactive premenopausal wo…